Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

19.44
-0.2600-1.32%
Post-market: 19.500.0600+0.31%19:56 EDT
Volume:2.97M
Turnover:58.13M
Market Cap:4.26B
PE:-12.42
High:20.17
Open:19.92
Low:19.18
Close:19.70
52wk High:21.27
52wk Low:3.43
Shares:219.14M
Float Shares:145.00M
Volume Ratio:1.41
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5651
EPS(LYR):-1.6113
ROE:-36.77%
ROA:-22.88%
PB:4.79
PE(LYR):-12.06

Loading ...

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

GlobeNewswire
·
May 06

Relay Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
May 02

Top Relay Therapeutics Executives Quietly Unload Shares in Coordinated Move

TIPRANKS
·
May 01

Relay Therapeutics to report first-quarter results after market close

Reuters
·
Apr 30

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

GlobeNewswire
·
Apr 30

Relay Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $19

THOMSON REUTERS
·
Apr 29

Relay Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Apr 28

Oppenheimer Adjusts Relay Therapeutics Price Target to $18 From $14, Maintains Outperform Rating

MT Newswires Live
·
Apr 28

Relay Therapeutics : Oppenheimer Raises Target Price to $18 From $14

THOMSON REUTERS
·
Apr 28

Relay Therapeutics price target raised to $21 from $17 at Wells Fargo

TIPRANKS
·
Apr 28

Relay Therapeutics price target raised to $19 from $17 at Citizens

TIPRANKS
·
Apr 28

Barclays Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

TIPRANKS
·
Apr 28

Relay Therapeutics Inc : Raymond James Raises Target Price to $23 From $19

THOMSON REUTERS
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Cormedix (CRMD) and Relay Therapeutics (RLAY)

TIPRANKS
·
Apr 28

Relay Therapeutics advances zovegalisib combo in breast cancer

TIPRANKS
·
Apr 27

Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer

TIPRANKS
·
Apr 27

Relay Therapeutics plans Phase 3 trial of zovegalisib-atirmociclib triplet in breast cancer

Reuters
·
Apr 27

Relay Therapeutics Inc - Enters Supply Agreement With Pfizer for Atirmociclib in Phase 3 Trial

THOMSON REUTERS
·
Apr 27

Relay Therapeutics Inc - Reports 44% Orr in Heavily Pre-Treated Cdk4/6-Experienced Breast Cancer Patients

THOMSON REUTERS
·
Apr 27

Relay Therapeutics Initiated at Hold by Jones Trading

Dow Jones
·
Apr 14